Brief: Cantargia Publishes Clinical Trial Results With Nadunolimab And Pembrolizumab
06/05/2025 06:40
May 6 (Reuters) - Cantargia AB CANTA.ST: PUBLISHES CLINICAL TRIAL RESULTS WITH NADUNOLIMAB AND PEMBROLIZUMAB TRIAL SHOWS ACCEPTABLE SAFETY PROFILE AND MEDIAN OVERALL SURVIVAL OF 19.7 MONTHS OBSERVED COMBINATION THERAPY SHOWS 60% DISEASE CONTROL RATE Source text: ID:nMFN1yG6FS Further company coverage: CANTA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))